Global EsophagealCancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan,Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumaband Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication(Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, SquamousCell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, RetailPharmacy, and Online Pharmacy), and By Region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 765.2 million in 2018 and is projected to exhibit a CAGR of 8.2% over theforecast period (2019 - 2027), as highlighted in a new report published by.
Increasing cancer research, Foodand Drug Administration (FDA) approvals-based drug discovery, and rising numberof development programs and pipeline drugs among others are the major factorsthat are expected to drive growth of the esophageal cancer drugs market.Various pharmaceutical companies are focused on research and development ofnovel drug therapies for the treatment of esophageal cancer drugs. Forinstance, in November 2018, Merck & Co., Inc. revealed the results of phase3 clinical trial of Keytruda (pembrolizumab), which indicates Keytruda reducedthe risk of death compared to chemotherapy in patients with squamous cellcarcinoma or adenocarcinoma. The overall survival rate of patients who consumedpembrolizumab was 43% whereas patients who consumed chemotherapy drugs such aspaclitaxel, docetaxel or irinotecan experienced 20% survival rate.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3036
Manufacturers in the esophagealcancer drugs market are focusing on increasing product portfolio by receivingFood and Drug Administration (FDA) approvals to further boost the esophagealcancer drug market size. In April 2014, FDA approved Cyramza (ramucirumab) foruse in combination with paclitaxel for the treatment of patients with advancedgastric or gastro-esophageal junction adenocarcinoma.
Browse 38 Market Data Tables and27 Figures spread through 166 Pages and in-depth TOC on "Esophageal CancerDrugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridineand Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, andCisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab andRamucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication(Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, SquamousCell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, RetailPharmacy, and Online Pharmacy), and By Region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa)
Many companies such as PfizerInc., Merck & Co., Bristol-Meyer Squibb, and Eli Lilly & Company arefocused on drugs that are under development in the pipeline such as Ipilimumaband Nivolumab and are expected to be launched in the near future. For instance,in 2018, Bristol-Meyer Squibb’s Opdivo (Nivolumab) intravenous infusioninjection and Yervoy Injection was in the developmental pipeline. It is inphase III for treatment of stomach cancer and is expected to launch in theU.S., Europe, South Korea, and Taiwan in the near future
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/esophageal-cancer-drugs-market-3036
Key Takeaways of the EsophagealCancer Drugs Market:
The global esophageal cancerdrugs market is expected to expand at a CAGR of 8.2% during the forecast period(2019–2027), owing to increasing research & development and demand forgenomic and repertoire sequencing-based research
Among therapy type, theimmunotherapy segment is expected to account for maximum share over theforecast period. For instance, in 2017, pembrolizumab (Keytruda) was approvedby the U.S. Food and Drug Administration (FDA) to treat gastroesophageal cancerin some patients whose previous treatment did not work or stopped working, andit was proved to be better than chemotherapy.
Major players operating in theglobal esophageal cancer drugs market include Amgen Inc., Eli Lilly andCompany, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, BoehringerIngelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG,Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, andMerck & Co.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3036
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
